Researchers at Stanford Medicine developed TCIP3, a two-headed experimental therapy that converts a cancer driver into a built-in kill switch rather than simply inhibiting or destroying the protein. The approach eliminated aggressive human lymphoma tumors in mouse models by reprogramming the target’s function into an anti-tumor state. The study describes a strategy that aims to maintain specificity while shifting downstream cellular outcomes toward death. Mechanistically, “molecular glue” concepts depend on inducing new interactions; TCIP3’s reported tumor eradication suggests the circuit is effective in vivo for lymphoma. If this translates beyond preclinical models, TCIP3-style conversion could become a platform for hard-to-drug oncogenic drivers where conventional inhibition produces limited durability.